Tirzepatide vs insulin for diabetes and brain effects
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests how tirzepatide and insulin glargine affect blood sugar, fat metabolism, and brain function in adults with type 2 diabetes. It may help researchers learn which treatment changes diabetes-related body and brain processes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes (not type 1 diabetes).
- You’ve been on stable metformin (with or without sulfonylureas) for at least 2 months and doses haven’t changed.
- You are not using insulin right now (except pregnancy-related or short-term insulin for up to 14 days).
- Your A1c blood test at the start is between 7.5% and 11.0%, and your BMI is at least 23.
- You do not have certain eye, pancreas, stomach-emptying, heart, liver, or kidney problems listed in the study. (Examples: pancreatitis history, major diabetic eye disease, gastroparesis, recent heart failure/heart attack/stroke, serious kidney disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares an AI-powered lifestyle program to a medication called tirzepatide for helping people with obesity and newly diagnosed type 2 diabetes lose weight and manage their blood sugar. It aims to find which approach works better and is safer.
This study tests if tirzepatide, a medicine that helps lower blood sugar and manage weight, is safe and effective for people with type 1 diabetes who are overweight or have obesity. You must already use an automated insulin pump system.
This study tests a medication called tirzepatide for people with type 1 diabetes who also have overweight or obesity. Tirzepatide may help with weight loss and blood sugar control, and you'll use a continuous glucose monitor throughout the study.
This trial tests if tirzepatide, a weekly injection, can help people with type 1 diabetes who are also overweight or obese. The goal is to see if it improves blood sugar control and supports weight loss.
This trial studies tirzepatide to see if it can slow the progression of coronary artery plaque in people with type 2 diabetes. It uses special heart CT scans to track changes over time.
This study tests if tirzepatide helps people with obesity lose weight, whether or not they have type 2 diabetes. It aims to see how safe and effective the drug is.
Hear when a new Type 2 Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.